Know Cancer

forgot password

A Phase II, Multicenter, Open Label, Two Stage Design Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase 2
18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

A Phase II, Multicenter, Open Label, Two Stage Design Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Inclusion Criteria

Inclusion criteria:

1. Males with histologically proven adenocarcinoma of the prostate that has progressed
(ie. a minimum of 3 consecutive rises in Prostate Specific Antigen (PSA) (with the
last value ≥ 4 ng/mL) taken at least 1 week apart prior to study entry) despite
castration or maintenance of castrate-level testosterone (defined as serum
testosterone ≤ .50 ng/dL or 1.7 nmol/L), or progressed during non-hormonal

Note: Patients previously treated with an antiandrogen must have disease progression
documented after antiandrogen withdrawal. Those who have not undergone orchiectomy
must continue medical castration with a gonadotropin-releasing hormone analog. At
least 4 weeks must have elapsed between the withdrawal of antiandrogens (6 weeks in
the case of nilutamide or bicalutamide and four weeks in the case of flutamide or
other secondary hormonal therapy) and enrollment, so as to avoid the possibility of
confounding results of the response due to antiandrogen withdrawal.

2. Patients must fulfill one of the following two criteria to be stratified:

- No prior chemotherapy (except mitoxantrone or estramustine) for advanced and/or
metastatic disease as defined in inclusion criteria #1.

- Failure of no more than one previous chemotherapeutic regimen with tubulin
binding agents such as docetaxel.

3. Resolution of all chemotherapy or radiation-related toxicities to less than grade 2
severity, except neuropathy and alopecia

4. Age ≥ 18 years.

5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

6. Life expectancy of ≥ 3 months.

7. Adequate renal function as evidenced by serum creatinine ≤ 1.5 times upper limits of
normal (ULN) or calculated creatinine clearance ≥ 40 mL/minute (min) per the
Cockcroft and Gault formula.

8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) ≥ 1.5 x
10^9/L, hemoglobin ≥ 9.0 g/dL (or 5.5 mmol/L), and platelet count ≥ 100 x 10^9/L.
Adequate liver function as evidenced by bilirubin ≤ 1.5 x ULN, alanine transaminase
(ALT), and aspartate transaminase (AST) ≤ 3 x ULN (in the case of liver metastases ≤
5 x ULN).

9. Patients willing and able to complete the VAS (Visual Analog Scale).

10. Patients willing and able to comply with the study protocol for the duration of the

11. Written informed consent prior to any study-specific screening procedures with the
understanding that the patient may withdraw consent at any time without prejudice.

Exclusion criteria:

1. Patients who have received chemotherapy, radiation, or experimental therapy within 4
weeks of start of E7389 treatment

2. Radiation therapy encompassing ≥30% of marrow or treatment with radioactive strontium

3. Patients who require therapeutic anti-coagulant therapy with warfarin or related
compounds; (mini dose warfarin or related compounds are permitted).

4. Severe / uncontrolled intercurrent illness/infection.

5. Significant cardiovascular impairment (history of congestive heart failure > NYHA
grade II, unstable angina or myocardial infarction within the past six months, or
serious cardiac arrhythmia)

6. Patients with organ allografts.

7. Patients with known immunosuppression such as positive HIV status.

8. Patients who have had a prior malignancy, other than nonmelanoma skin cancer, unless
the prior malignancy was diagnosed and definitively treated ≥ 5 years previously with
no subsequent evidence of recurrence.

9. Patients with pre-existing neuropathy > Grade 2

10. Patients with brain or subdural metastases are not eligible, except if they have
completed local therapy and have discontinued the use of corticosteroids for this
indication for at least two weeks before starting treatment with E7389.

11. Patients with meningeal carcinomatosis.

12. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical

13. Patients who participated in a prior E7389 clinical trial.

14. Patients with other significant disease or disorders that, in the Investigator's
opinion, would exclude the patient from the study.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria

Outcome Description:

Bubley Criteria: Patients must have progressive disease to enter study. For outcomes, PSA response must show at least 50% decrease. Duration of response is the time from >50% decrease from baseline to when there is a 50% decrease in nadir. PSA progressive disease- 25% increase from baseline or increase of 5 ng/mL along with measureable disease Stable disease- decline of less than 50% and not more than 25% increase.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Asha Das

Investigator Role:

Study Director

Investigator Affiliation:

Eisai Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

January 2006

Completion Date:

January 2008

Related Keywords:

  • Prostate Cancer
  • Prostate cancer
  • metastatic disease
  • Neoplasm Metastasis
  • Prostatic Neoplasms



Virginia Oncology Associates Newport News, Virginia  23606
Missouri Cancer Associates Columbia, Missouri  65201
Mary Crowley Medical Research Center Dallas, Texas  75246
Tyler Cancer Center Tyler, Texas  75702
New York Oncology Hematology, P.C. Albany, New York  12208
Central Indiana Cancer Centers Indianapolis, Indiana  46227
El Paso Cancer Treatment Center El Paso, Texas  79915
Columbia University Medical Center New York, New York  10032
Deke Slayton Cancer Center Webster, Texas  77589
US Oncology Houston, Texas  77060
Texas Oncology PA Dallas, Texas  75231
Melbourne Internal Medicine Associates Melbourne, Florida  32901
Dr. Robert Jotte Denver, Colorado  80218
Ocala Oncology Center PL Ocala, Florida  34474
Minnesota Hematology Oncology Burnsville, Minnesota  33557
St. Luke's Roosevelt Hospital Center New York, New York  10019
Raleigh Hematology Oncology Associates PL Raleigh, North Carolina  27607